Do analysts rate PMCB or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, PMCB or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvilex N/A N/A $30.66M -$1.12 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is PMCB or VIRI more profitable?

Nuvilex's return on equity of 2.13% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Virios Therapeutics N/A -130.33% -115.00%

Do analysts rate PMCB or DARE?

Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 402.26%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is PMCB or DARE more profitable?

Nuvilex's return on equity of 2.13% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Dare Bioscience N/A N/A -46.22%

Do analysts prefer APLM or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, APLM or PMCB?

Nuvilex has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.55 -$10.94M N/A N/A Nuvilex N/A N/A $30.66M -$1.12 N/A

Is APLM or PMCB more profitable?

Nuvilex's return on equity of 2.13% beat Apollomics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Nuvilex N/A 2.13% 1.69%

Do analysts recommend SNTI or PMCB?

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 939.50%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Nuvilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or PMCB more profitable?

Nuvilex's return on equity of 2.13% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Nuvilex N/A 2.13% 1.69%

Do analysts prefer PMCB or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PMCB or TAOX more profitable?

Nuvilex's return on equity of 2.13% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Nuvilex N/A 2.13% 1.69% Synaptogenix N/A -163.40% -133.47%

Nuvilex (PMCB) Competitors

$0.80 +0.04 (+4.60%)

As of 02:54 PM Eastern

Compare

PMCB vs. VIRI, DARE, APLM, SNTI, and TAOX

Should you buy Nuvilex stock or one of its competitors? MarketBeat compares Nuvilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvilex include Virios Therapeutics (VIRI), Dare Bioscience (DARE), Apollomics (APLM), Senti Biosciences (SNTI), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry.

How does Nuvilex compare to Virios Therapeutics?

Nuvilex (NASDAQ:PMCB) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Nuvilex has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

In the previous week, Nuvilex had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Nuvilex and 0 mentions for Virios Therapeutics. Nuvilex's average media sentiment score of 1.87 beat Virios Therapeutics' score of 0.00 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Virios Therapeutics	Neutral

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Nuvilex's return on equity of 2.13% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

Nuvilex beats Virios Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Nuvilex compare to Dare Bioscience?

Nuvilex (NASDAQ:PMCB) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Nuvilex has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Nuvilex's return on equity of 2.13% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Dare Bioscience	N/A	N/A	-46.22%

In the previous week, Nuvilex and Nuvilex both had 1 articles in the media. Dare Bioscience's average media sentiment score of 1.89 beat Nuvilex's score of 1.87 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Very Positive
Dare Bioscience	Very Positive

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 11.0% of Nuvilex shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 402.26%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nuvilex has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Dare Bioscience	$1.03M	28.96	-$13.40M	-$0.95	N/A

Summary

Dare Bioscience beats Nuvilex on 7 of the 13 factors compared between the two stocks.

How does Nuvilex compare to Apollomics?

Apollomics (NASDAQ:APLM) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Nuvilex's return on equity of 2.13% beat Apollomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Nuvilex	N/A	2.13%	1.69%

19.1% of Apollomics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Apollomics had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.87 beat Apollomics' score of 1.44 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Positive
Nuvilex	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.55	-$10.94M	N/A	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Summary

Nuvilex beats Apollomics on 6 of the 9 factors compared between the two stocks.

How does Nuvilex compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Senti Biosciences has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Nuvilex has lower revenue, but higher earnings than Senti Biosciences. Nuvilex is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$38K	788.46	-$61.44M	-$1.92	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Nuvilex's return on equity of 2.13% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Nuvilex	N/A	2.13%	1.69%

Senti Biosciences presently has a consensus target price of $10.00, indicating a potential upside of 939.50%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Senti Biosciences had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Senti Biosciences and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.87 beat Senti Biosciences' score of 0.93 indicating that Nuvilex is being referred to more favorably in the news media.

Company	Overall Sentiment
Senti Biosciences	Positive
Nuvilex	Very Positive

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 11.0% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Senti Biosciences beats Nuvilex on 8 of the 15 factors compared between the two stocks.

How does Nuvilex compare to Synaptogenix?

Nuvilex (NASDAQ:PMCB) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Nuvilex's return on equity of 2.13% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Synaptogenix	N/A	-163.40%	-133.47%

In the previous week, Synaptogenix had 1 more articles in the media than Nuvilex. MarketBeat recorded 2 mentions for Synaptogenix and 1 mentions for Nuvilex. Nuvilex's average media sentiment score of 1.87 beat Synaptogenix's score of 1.28 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Very Positive
Synaptogenix	Positive

Nuvilex has higher earnings, but lower revenue than Synaptogenix. Nuvilex is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Synaptogenix	$687.84K	43.18	-$28.74M	-$13.28	N/A

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nuvilex has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nuvilex beats Synaptogenix on 7 of the 11 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.55M	$2.98B	$6.48B	$12.36B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.71	18.53	23.95	24.60
Price / Sales	N/A	461.29	536.37	171.61
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.11	4.00	10.44	6.77
Net Income	$30.66M	$75.79M	$3.56B	$337.32M
7 Day Performance	13.71%	1.96%	0.83%	2.06%
1 Month Performance	-1.04%	-0.35%	1.78%	3.93%
1 Year Performance	-20.40%	23.23%	25.59%	32.29%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	1.5077 of 5 stars	$0.80 +4.6%	N/A	-23.9%	$8.55M	N/A	N/A	4	Positive News
VIRI Virios Therapeutics	N/A	$1.61 -3.6%	N/A	-66.9%	$31.01M	N/A	N/A	5	Gap Up
DARE Dare Bioscience	2.4202 of 5 stars	$2.18 +6.3%	$10.00 +358.7%	-33.3%	$30.71M	$1.16M	N/A	30	Positive News
APLM Apollomics	1.6644 of 5 stars	$14.00 +0.6%	N/A	+114.7%	$30.57M	$8.50M	N/A	45	Positive News Short Interest Decrease Gap Down
SNTI Senti Biosciences	3.4647 of 5 stars	$1.00 +2.5%	$8.75 +775.0%	-63.1%	$30.38M	$20K	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. VIRI, DARE, APLM, SNTI, and TAOX

How does Nuvilex compare to Virios Therapeutics?

Summary

How does Nuvilex compare to Dare Bioscience?

Summary

How does Nuvilex compare to Apollomics?

Summary

How does Nuvilex compare to Senti Biosciences?

Summary

How does Nuvilex compare to Synaptogenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. VIRI, DARE, APLM, SNTI, and TAOX

How does Nuvilex compare to Virios Therapeutics?

Which has more risk and volatility, PMCB or VIRI?

Does the media favor PMCB or VIRI?

Do insiders and institutionals have more ownership in PMCB or VIRI?

Do analysts rate PMCB or VIRI?

Which has better valuation & earnings, PMCB or VIRI?

Is PMCB or VIRI more profitable?

Summary

How does Nuvilex compare to Dare Bioscience?

Which has more volatility & risk, PMCB or DARE?

Is PMCB or DARE more profitable?

Does the media refer more to PMCB or DARE?

Do institutionals and insiders have more ownership in PMCB or DARE?

Do analysts rate PMCB or DARE?

Which has stronger valuation and earnings, PMCB or DARE?

Summary

How does Nuvilex compare to Apollomics?

Is APLM or PMCB more profitable?

Do institutionals and insiders have more ownership in APLM or PMCB?

Does the media refer more to APLM or PMCB?

Do analysts prefer APLM or PMCB?

Which has stronger earnings and valuation, APLM or PMCB?

Which has more risk and volatility, APLM or PMCB?

Summary

How does Nuvilex compare to Senti Biosciences?

Which has more risk and volatility, SNTI or PMCB?

Which has preferable earnings & valuation, SNTI or PMCB?

Is SNTI or PMCB more profitable?

Do analysts recommend SNTI or PMCB?

Does the media prefer SNTI or PMCB?

Do institutionals & insiders believe in SNTI or PMCB?

Summary

How does Nuvilex compare to Synaptogenix?

Is PMCB or TAOX more profitable?

Does the media favor PMCB or TAOX?

Which has preferable earnings and valuation, PMCB or TAOX?

Do institutionals and insiders hold more shares of PMCB or TAOX?

Which has more risk and volatility, PMCB or TAOX?

Do analysts prefer PMCB or TAOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools